Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Preclinical Core

Composition of the Biology STEERING CommittEe:
  • Prof. Stefan Pfister, DKFZ, Heidelberg, GE - Chair of the committee
  • Prof. Louis Chesler, Royal Marsden, London, UK
  • Dr. David Jones, DKFZ, Heidelberg, GE
  • Dr. Johannes Schulte, Charité Berlin, Berlin, GE
  • Dr. Jan Molenaar, AMC, Amsterdam, NL
  • Dr. Monique Den Boer, Erasmus MC, Rotterdam, NL
  • Dr. Gudrun Schleiermacher, Institut Curie, Paris, FR
  • Prof. Jean Pierre Bourquin, University Children's Hospital, Zuerich, SWIT
  • Dr. Heinrich Kovar, CCRI, Vienna, AU


To select and prioritise anti-cancer compounds being developed in adults by :

  • Identifying targets in paediatric primary tumours and relevant tumour models,
  • Determining the target-dependency on paediatric tumour models,
  • Testing new (targeted and non-targeted compounds) in pre-clinical in vitro and in vivo models.

ITCC has designed a rational mechanism-based strategy for compound prioritisation based on target genes and protein expression profiles, target validation and preclinical evaluation in relevant in vitro and in vivo models.


The pre-clinical stepwise evaluation of drugs in ITCC consists of :

  • Target presence screening
  • In vitro efficacy testing
  • Target validation (tumour dependency)
  • In vivo proof of principle testing


To identify drugable biological targets which are specific for paediatric malignanciesIn order to develop innovative treatment through the Kids Cancer Kinome (KCK) project funded by the European Commission in the 6th Framework Program for Research and Development. :

  • Exploring the role of kinases through functional knockout and mutation analysis
  • Validating selected kinases in vitro and in vivo cell lines and transplantable experimental models
  • Developing LNA inhibitors for selected kinases